The Mood Disorder Cohort Research Consortium (MDCRC) study is designed as a naturalistic observational prospective cohort study for early-onset mood disorders (major depressive disorders, bipolar disorders type 1 and 2) in South Korea. The study subjects consist of two populations: 1) patients with mood disorders under 25 years old and 2) patients with mood disorders within 2 years of treatment under 35 years old. After successful screening, the subjects are evaluated using baseline assessments and serial follow-up assessments at 3-month intervals. Between the follow-up assessments, subjects are dictated to check their own daily mood status before bedtime using the eMood chart application or a paper mood diary. At the regular visits every 3 months, inter-visit assessments are evaluated based on daily mood charts and interviews with patients. In addition to the daily mood chart, sleep quality, inter-visit major and minor mood episodes, stressful life events, and medical usage pattern with medical expenses are also assessed. Genomic DNA from blood is obtained for genomic analyses. From the MDCRC study, the clinical course, prognosis, and related factors of early-onset mood disorders can be clarified. The MDCRC is also able to facilitate translational research for mood disorders and provide a resource for the convergence study of mood disorders.
Aims. Assess bipolar disorder (BD) subtype and treatment location effects on BD core pharmacotherapy.
Methods. Outpatients not in a syndromal episode referred to University of Milan and Stanford University BD Clinics were assessed with SCID for DSM-IV, and the STEP-BD ADE, respectively. Prevalence and clinical correlates of antidepressant (AD), antipsychotic (AP), and mood stabilizer (MS) use, in aggregate and individually, were compared in bipolar I (BDI) versus II (BDII) patients in Milan/Stanford and in Milan versus Stanford patients, stratified by subtype. Results. Milan/Stanford pooled BDI versus BDII patients significantly more often took APs (69.8% versus 44.8%), MSs (68.6% versus 57.7%), and valproate (40.1% % versus 17.5%), less often ADs (23.1% versus 55.6%) and lamotrigine (9.9% versus 25.2%). Milan versus Stanford patients (stratified by BD subtype) significantly more often took APs (BDI and BDII), ADs (BDII), and valproate (BDII), less often lamotrigine (BDI). Conclusion. Milan/Stanford pooled BDI versus BDII patients significantly more often took APs, MSs, and valproate, less often ADs and lamotrigine. Milan versus Stanford patients more often took APs (BDI and BDII), ADs (BDII), and valproate (BDII), less often lamotrigine (BDI). Research regarding BD core pharmacotherapy relationships with bipolar subtype and treatment location is warranted to enhance clinical management.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.